281 related articles for article (PubMed ID: 33402827)
1. Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.
Asaoka M; Gandhi S; Ishikawa T; Takabe K
Breast Cancer (Auckl); 2020; 14():1178223420980377. PubMed ID: 33402827
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
3. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
[TBL] [Abstract][Full Text] [Related]
4. Locally advanced breast cancer.
Sikov WM
Curr Treat Options Oncol; 2000 Aug; 1(3):228-38. PubMed ID: 12057165
[TBL] [Abstract][Full Text] [Related]
5. The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer.
Oikawa M
Chin Clin Oncol; 2020 Jun; 9(3):29. PubMed ID: 32576021
[TBL] [Abstract][Full Text] [Related]
6. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
7. Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.
Matthews CM; Nymberg K; Berger M; Vargo CA; Dempsey J; Li J; Ramaswamy B; Reinbolt R; Sardesai S; Wesolowski R; Williams N; Lustberg M
J Oncol Pharm Pract; 2020 Apr; 26(3):572-579. PubMed ID: 31256745
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
[TBL] [Abstract][Full Text] [Related]
9. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
10. Current and future role of neoadjuvant therapy for breast cancer.
Untch M; Konecny GE; Paepke S; von Minckwitz G
Breast; 2014 Oct; 23(5):526-37. PubMed ID: 25034931
[TBL] [Abstract][Full Text] [Related]
11. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.
Foldi J; Rozenblit M; Park TS; Knowlton CA; Golshan M; Moran M; Pusztai L
Curr Treat Options Oncol; 2021 Jul; 22(9):79. PubMed ID: 34213636
[TBL] [Abstract][Full Text] [Related]
12. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.
Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC
Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of a Multidisciplinary Team in the Management of Patients with Early-Stage Breast Cancer Undergoing Neoadjuvant Chemotherapy at a Community Cancer Center.
Bhardwaj PV; Mason H; Kaufman SA; Visintainer P; Makari-Judson G
Curr Oncol; 2023 May; 30(5):4861-4870. PubMed ID: 37232824
[No Abstract] [Full Text] [Related]
14. Regarding: Valero V, Buzdar AU, Hortobagyi GN. "Locally Advanced Breast Cancer," The Oncologist 1996;1:8-17.
Oliver RT
Oncologist; 1996; 1(4):278-279. PubMed ID: 10388003
[TBL] [Abstract][Full Text] [Related]
15. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
Zeidman M; Alberty-Oller JJ; Ru M; Pisapati KV; Moshier E; Ahn S; Mazumdar M; Port E; Schmidt H
Breast Cancer Res Treat; 2020 Nov; 184(1):203-212. PubMed ID: 32740807
[TBL] [Abstract][Full Text] [Related]
16. [The development of neoadjuvant chemotherapy in breast cancer].
Taguchi T
Gan To Kagaku Ryoho; 2012 Jun; 39(6):876-81. PubMed ID: 22705682
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast Cancer.
Wang M; Hou L; Chen M; Zhou Y; Liang Y; Wang S; Jiang J; Zhang Y
Sci Rep; 2017 Mar; 7():44673. PubMed ID: 28327615
[TBL] [Abstract][Full Text] [Related]
18. Risk factors of breast cancer recurrence in pathologic complete response achieved by patients following neoadjuvant chemotherapy: a single-center retrospective study.
Choi JY; Woen D; Jang SY; Lee H; Shin DS; Kwak Y; Lee H; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
Front Oncol; 2023; 13():1230310. PubMed ID: 37849818
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
